<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231225071446&amp;v=2.18.0&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231225071446&amp;v=2.18.0&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0)</generator>
<language>en</language>
<lastbuilddate>Mon, 25 Dec 2023 12:14:48 +0000</lastbuilddate>
<pubDate>Sat, 23 Dec 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>More blood for patients with myocardial infarction and anaemia?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38141126/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231225071446&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 23:ehad832. doi: 10.1093/eurheartj/ehad832. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38141126/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231225071446&v=2.18.0">38141126</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad832>10.1093/eurheartj/ehad832</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38141126</guid>
<pubDate>Sat, 23 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:date>2023-12-23</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>More blood for patients with myocardial infarction and anaemia?</dc:title>
<dc:identifier>pmid:38141126</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad832</dc:identifier>
</item>
<item>
<title>Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38134933/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231225071446&amp;v=2.18.0
      <description>Deciphering the cell-state transitions underlying immune adaptation across time is fundamental for advancing biology. Empirical in vivo genomic technologies that capture cellular dynamics are currently lacking. We present Zman-seq, a single-cell technology recording transcriptomic dynamics across time by introducing time stamps into circulating immune cells, tracking them in tissues for days. Applying Zman-seq resolved cell-state and molecular trajectories of the dysfunctional immune...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Dec 13:S0092-8674(23)01317-X. doi: 10.1016/j.cell.2023.11.032. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Deciphering the cell-state transitions underlying immune adaptation across time is fundamental for advancing biology. Empirical in vivo genomic technologies that capture cellular dynamics are currently lacking. We present Zman-seq, a single-cell technology recording transcriptomic dynamics across time by introducing time stamps into circulating immune cells, tracking them in tissues for days. Applying Zman-seq resolved cell-state and molecular trajectories of the dysfunctional immune microenvironment in glioblastoma. Within 24 hours of tumor infiltration, cytotoxic natural killer cells transitioned to a dysfunctional program regulated by TGFB1 signaling. Infiltrating monocytes differentiated into immunosuppressive macrophages, characterized by the upregulation of suppressive myeloid checkpoints Trem2, Il18bp, and Arg1, over 36 to 48 hours. Treatment with an antagonistic anti-TREM2 antibody reshaped the tumor microenvironment by redirecting the monocyte trajectory toward pro-inflammatory macrophages. Zman-seq is a broadly applicable technology, enabling empirical measurements of differentiation trajectories, which can enhance the development of more efficacious immunotherapies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38134933/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231225071446&v=2.18.0">38134933</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.032>10.1016/j.cell.2023.11.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38134933</guid>
<pubDate>Fri, 22 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Daniel Kirschenbaum</dc:creator>
<dc:creator>Ken Xie</dc:creator>
<dc:creator>Florian Ingelfinger</dc:creator>
<dc:creator>Yonatan Katzenelenbogen</dc:creator>
<dc:creator>Kathleen Abadie</dc:creator>
<dc:creator>Thomas Look</dc:creator>
<dc:creator>Fadi Sheban</dc:creator>
<dc:creator>Truong San Phan</dc:creator>
<dc:creator>Baoguo Li</dc:creator>
<dc:creator>Pascale Zwicky</dc:creator>
<dc:creator>Ido Yofe</dc:creator>
<dc:creator>Eyal David</dc:creator>
<dc:creator>Kfir Mazuz</dc:creator>
<dc:creator>Jinchao Hou</dc:creator>
<dc:creator>Yun Chen</dc:creator>
<dc:creator>Hila Shaim</dc:creator>
<dc:creator>Mayra Shanley</dc:creator>
<dc:creator>Soeren Becker</dc:creator>
<dc:creator>Jiawen Qian</dc:creator>
<dc:creator>Marco Colonna</dc:creator>
<dc:creator>Florent Ginhoux</dc:creator>
<dc:creator>Katayoun Rezvani</dc:creator>
<dc:creator>Fabian J Theis</dc:creator>
<dc:creator>Nir Yosef</dc:creator>
<dc:creator>Tobias Weiss</dc:creator>
<dc:creator>Assaf Weiner</dc:creator>
<dc:creator>Ido Amit</dc:creator>
<dc:date>2023-12-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma</dc:title>
<dc:identifier>pmid:38134933</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.032</dc:identifier>
</item>
<item>
<title>Sensory neurons promote immune homeostasis in the lung</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38134932/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231225071446&amp;v=2.18.0
      <description>Cytokines employ downstream Janus kinases (JAKs) to promote chronic inflammatory diseases. JAK1-dependent type 2 cytokines drive allergic inflammation, and patients with JAK1 gain-of-function (GoF) variants develop atopic dermatitis (AD) and asthma. To explore tissue-specific functions, we inserted a human JAK1 GoF variant (JAK1^(GoF)) into mice and observed the development of spontaneous AD-like skin disease but unexpected resistance to lung inflammation when JAK1^(GoF) expression was...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Dec 13:S0092-8674(23)01313-2. doi: 10.1016/j.cell.2023.11.027. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cytokines employ downstream Janus kinases (JAKs) to promote chronic inflammatory diseases. JAK1-dependent type 2 cytokines drive allergic inflammation, and patients with JAK1 gain-of-function (GoF) variants develop atopic dermatitis (AD) and asthma. To explore tissue-specific functions, we inserted a human JAK1 GoF variant (JAK1<sup>GoF</sup>) into mice and observed the development of spontaneous AD-like skin disease but unexpected resistance to lung inflammation when JAK1<sup>GoF</sup> expression was restricted to the stroma. We identified a previously unrecognized role for JAK1 in vagal sensory neurons in suppressing airway inflammation. Additionally, expression of Calcb/CGRPβ was dependent on JAK1 in the vagus nerve, and CGRPβ suppressed group 2 innate lymphoid cell function and allergic airway inflammation. Our findings reveal evolutionarily conserved but distinct functions of JAK1 in sensory neurons across tissues. This biology raises the possibility that therapeutic JAK inhibitors may be further optimized for tissue-specific efficacy to enhance precision medicine in the future.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38134932/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231225071446&v=2.18.0">38134932</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.027>10.1016/j.cell.2023.11.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38134932</guid>
<pubDate>Fri, 22 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Masato Tamari</dc:creator>
<dc:creator>Kate L Del Bel</dc:creator>
<dc:creator>Aaron M Ver Heul</dc:creator>
<dc:creator>Lydia Zamidar</dc:creator>
<dc:creator>Keisuke Orimo</dc:creator>
<dc:creator>Masato Hoshi</dc:creator>
<dc:creator>Anna M Trier</dc:creator>
<dc:creator>Hiroshi Yano</dc:creator>
<dc:creator>Ting-Lin Yang</dc:creator>
<dc:creator>Catherine M Biggs</dc:creator>
<dc:creator>Kenichiro Motomura</dc:creator>
<dc:creator>Rintaro Shibuya</dc:creator>
<dc:creator>Chuyue D Yu</dc:creator>
<dc:creator>Zili Xie</dc:creator>
<dc:creator>Hisato Iriki</dc:creator>
<dc:creator>Zhen Wang</dc:creator>
<dc:creator>Kelsey Auyeung</dc:creator>
<dc:creator>Gargi Damle</dc:creator>
<dc:creator>Deniz Demircioglu</dc:creator>
<dc:creator>Jill K Gregory</dc:creator>
<dc:creator>Dan Hasson</dc:creator>
<dc:creator>Jinye Dai</dc:creator>
<dc:creator>Rui B Chang</dc:creator>
<dc:creator>Hideaki Morita</dc:creator>
<dc:creator>Kenji Matsumoto</dc:creator>
<dc:creator>Sanjay Jain</dc:creator>
<dc:creator>Steven Van Dyken</dc:creator>
<dc:creator>Joshua D Milner</dc:creator>
<dc:creator>Dusan Bogunovic</dc:creator>
<dc:creator>Hongzhen Hu</dc:creator>
<dc:creator>David Artis</dc:creator>
<dc:creator>Stuart E Turvey</dc:creator>
<dc:creator>Brian S Kim</dc:creator>
<dc:date>2023-12-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Sensory neurons promote immune homeostasis in the lung</dc:title>
<dc:identifier>pmid:38134932</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.027</dc:identifier>
</item>
<item>
<title>Automatic cell-type harmonization and integration across Human Cell Atlas datasets</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38134877/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231225071446&amp;v=2.18.0
      <description>Harmonizing cell types across the single-cell community and assembling them into a common framework is central to building a standardized Human Cell Atlas. Here, we present CellHint, a predictive clustering tree-based tool to resolve cell-type differences in annotation resolution and technical biases across datasets. CellHint accurately quantifies cell-cell transcriptomic similarities and places cell types into a relationship graph that hierarchically defines shared and unique cell subtypes....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Dec 21;186(26):5876-5891.e20. doi: 10.1016/j.cell.2023.11.026.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Harmonizing cell types across the single-cell community and assembling them into a common framework is central to building a standardized Human Cell Atlas. Here, we present CellHint, a predictive clustering tree-based tool to resolve cell-type differences in annotation resolution and technical biases across datasets. CellHint accurately quantifies cell-cell transcriptomic similarities and places cell types into a relationship graph that hierarchically defines shared and unique cell subtypes. Application to multiple immune datasets recapitulates expert-curated annotations. CellHint also reveals underexplored relationships between healthy and diseased lung cell states in eight diseases. Furthermore, we present a workflow for fast cross-dataset integration guided by harmonized cell types and cell hierarchy, which uncovers underappreciated cell types in adult human hippocampus. Finally, we apply CellHint to 12 tissues from 38 datasets, providing a deeply curated cross-tissue database with ∼3.7 million cells and various machine learning models for automatic cell annotation across human tissues.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38134877/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231225071446&v=2.18.0">38134877</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.026>10.1016/j.cell.2023.11.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38134877</guid>
<pubDate>Fri, 22 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Chuan Xu</dc:creator>
<dc:creator>Martin Prete</dc:creator>
<dc:creator>Simone Webb</dc:creator>
<dc:creator>Laura Jardine</dc:creator>
<dc:creator>Benjamin J Stewart</dc:creator>
<dc:creator>Regina Hoo</dc:creator>
<dc:creator>Peng He</dc:creator>
<dc:creator>Kerstin B Meyer</dc:creator>
<dc:creator>Sarah A Teichmann</dc:creator>
<dc:date>2023-12-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Automatic cell-type harmonization and integration across Human Cell Atlas datasets</dc:title>
<dc:identifier>pmid:38134877</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.026</dc:identifier>
</item>
<item>
<title>Spatially coordinated heterochromatinization of long synaptic genes in fragile X syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38134876/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231225071446&amp;v=2.18.0
      <description>Short tandem repeat (STR) instability causes transcriptional silencing in several repeat expansion disorders. In fragile X syndrome (FXS), mutation-length expansion of a CGG STR represses FMR1 via local DNA methylation. Here, we find megabase-scale H3K9me3 domains on autosomes and encompassing FMR1 on the X chromosome in FXS patient-derived iPSCs, iPSC-derived neural progenitors, EBV-transformed lymphoblasts, and brain tissue with mutation-length CGG expansion. H3K9me3 domains connect via...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Dec 21;186(26):5840-5858.e36. doi: 10.1016/j.cell.2023.11.019.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Short tandem repeat (STR) instability causes transcriptional silencing in several repeat expansion disorders. In fragile X syndrome (FXS), mutation-length expansion of a CGG STR represses FMR1 via local DNA methylation. Here, we find megabase-scale H3K9me3 domains on autosomes and encompassing FMR1 on the X chromosome in FXS patient-derived iPSCs, iPSC-derived neural progenitors, EBV-transformed lymphoblasts, and brain tissue with mutation-length CGG expansion. H3K9me3 domains connect via inter-chromosomal interactions and demarcate severe misfolding of TADs and loops. They harbor long synaptic genes replicating at the end of S phase, replication-stress-induced double-strand breaks, and STRs prone to stepwise somatic instability. CRISPR engineering of the mutation-length CGG to premutation length reverses H3K9me3 on the X chromosome and multiple autosomes, refolds TADs, and restores gene expression. H3K9me3 domains can also arise in normal-length iPSCs created with perturbations linked to genome instability, suggesting their relevance beyond FXS. Our results reveal Mb-scale heterochromatinization and trans interactions among loci susceptible to instability.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38134876/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231225071446&v=2.18.0">38134876</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.019>10.1016/j.cell.2023.11.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38134876</guid>
<pubDate>Fri, 22 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Thomas Malachowski</dc:creator>
<dc:creator>Keerthivasan Raanin Chandradoss</dc:creator>
<dc:creator>Ravi Boya</dc:creator>
<dc:creator>Linda Zhou</dc:creator>
<dc:creator>Ashley L Cook</dc:creator>
<dc:creator>Chuanbin Su</dc:creator>
<dc:creator>Kenneth Pham</dc:creator>
<dc:creator>Spencer A Haws</dc:creator>
<dc:creator>Ji Hun Kim</dc:creator>
<dc:creator>Han-Seul Ryu</dc:creator>
<dc:creator>Chunmin Ge</dc:creator>
<dc:creator>Jennifer M Luppino</dc:creator>
<dc:creator>Son C Nguyen</dc:creator>
<dc:creator>Katelyn R Titus</dc:creator>
<dc:creator>Wanfeng Gong</dc:creator>
<dc:creator>Owen Wallace</dc:creator>
<dc:creator>Eric F Joyce</dc:creator>
<dc:creator>Hao Wu</dc:creator>
<dc:creator>Luis Alejandro Rojas</dc:creator>
<dc:creator>Jennifer E Phillips-Cremins</dc:creator>
<dc:date>2023-12-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Spatially coordinated heterochromatinization of long synaptic genes in fragile X syndrome</dc:title>
<dc:identifier>pmid:38134876</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.019</dc:identifier>
</item>
<item>
<title>Structural evolution of fibril polymorphs during amyloid assembly</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38134875/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231225071446&amp;v=2.18.0
      <description>Cryoelectron microscopy (cryo-EM) has provided unprecedented insights into amyloid fibril structures, including those associated with disease. However, these structures represent the endpoints of long assembly processes, and their relationship to fibrils formed early in assembly is unknown. Consequently, whether different fibril architectures, with potentially different pathological properties, form during assembly remains unknown. Here, we used cryo-EM to determine structures of amyloid fibrils...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Dec 21;186(26):5798-5811.e26. doi: 10.1016/j.cell.2023.11.025.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cryoelectron microscopy (cryo-EM) has provided unprecedented insights into amyloid fibril structures, including those associated with disease. However, these structures represent the endpoints of long assembly processes, and their relationship to fibrils formed early in assembly is unknown. Consequently, whether different fibril architectures, with potentially different pathological properties, form during assembly remains unknown. Here, we used cryo-EM to determine structures of amyloid fibrils at different times during in vitro fibrillation of a disease-related variant of human islet amyloid polypeptide (IAPP-S20G). Strikingly, the fibrils formed in the lag, growth, and plateau phases have different structures, with new forms appearing and others disappearing as fibrillation proceeds. A time course with wild-type hIAPP also shows fibrils changing with time, suggesting that this is a general property of IAPP amyloid assembly. The observation of transiently populated fibril structures has implications for understanding amyloid assembly mechanisms with potential new insights into amyloid progression in disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38134875/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231225071446&v=2.18.0">38134875</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.025>10.1016/j.cell.2023.11.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38134875</guid>
<pubDate>Fri, 22 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Martin Wilkinson</dc:creator>
<dc:creator>Yong Xu</dc:creator>
<dc:creator>Dev Thacker</dc:creator>
<dc:creator>Alexander I P Taylor</dc:creator>
<dc:creator>Declan G Fisher</dc:creator>
<dc:creator>Rodrigo U Gallardo</dc:creator>
<dc:creator>Sheena E Radford</dc:creator>
<dc:creator>Neil A Ranson</dc:creator>
<dc:date>2023-12-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Structural evolution of fibril polymorphs during amyloid assembly</dc:title>
<dc:identifier>pmid:38134875</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.025</dc:identifier>
</item>
<item>
<title>LRRC37B is a human modifier of voltage-gated sodium channels and axon excitability in cortical neurons</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38134874/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231225071446&amp;v=2.18.0
      <description>The enhanced cognitive abilities characterizing the human species result from specialized features of neurons and circuits. Here, we report that the hominid-specific gene LRRC37B encodes a receptor expressed in human cortical pyramidal neurons (CPNs) and selectively localized to the axon initial segment (AIS), the subcellular compartment triggering action potentials. Ectopic expression of LRRC37B in mouse CPNs in vivo leads to reduced intrinsic excitability, a distinctive feature of some classes...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Dec 21;186(26):5766-5783.e25. doi: 10.1016/j.cell.2023.11.028.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The enhanced cognitive abilities characterizing the human species result from specialized features of neurons and circuits. Here, we report that the hominid-specific gene LRRC37B encodes a receptor expressed in human cortical pyramidal neurons (CPNs) and selectively localized to the axon initial segment (AIS), the subcellular compartment triggering action potentials. Ectopic expression of LRRC37B in mouse CPNs in vivo leads to reduced intrinsic excitability, a distinctive feature of some classes of human CPNs. Molecularly, LRRC37B binds to the secreted ligand FGF13A and to the voltage-gated sodium channel (Nav) β-subunit SCN1B. LRRC37B concentrates inhibitory effects of FGF13A on Nav channel function, thereby reducing excitability, specifically at the AIS level. Electrophysiological recordings in adult human cortical slices reveal lower neuronal excitability in human CPNs expressing LRRC37B. LRRC37B thus acts as a species-specific modifier of human neuron excitability, linking human genome and cell evolution, with important implications for human brain function and diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38134874/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231225071446&v=2.18.0">38134874</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.028>10.1016/j.cell.2023.11.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38134874</guid>
<pubDate>Fri, 22 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Baptiste Libé-Philippot</dc:creator>
<dc:creator>Amélie Lejeune</dc:creator>
<dc:creator>Keimpe Wierda</dc:creator>
<dc:creator>Nikolaos Louros</dc:creator>
<dc:creator>Emir Erkol</dc:creator>
<dc:creator>Ine Vlaeminck</dc:creator>
<dc:creator>Sofie Beckers</dc:creator>
<dc:creator>Vaiva Gaspariunaite</dc:creator>
<dc:creator>Angéline Bilheu</dc:creator>
<dc:creator>Katerina Konstantoulea</dc:creator>
<dc:creator>Hajnalka Nyitrai</dc:creator>
<dc:creator>Matthias De Vleeschouwer</dc:creator>
<dc:creator>Kristel M Vennekens</dc:creator>
<dc:creator>Niels Vidal</dc:creator>
<dc:creator>Thomas W Bird</dc:creator>
<dc:creator>Daniela C Soto</dc:creator>
<dc:creator>Tom Jaspers</dc:creator>
<dc:creator>Maarten Dewilde</dc:creator>
<dc:creator>Megan Y Dennis</dc:creator>
<dc:creator>Frederic Rousseau</dc:creator>
<dc:creator>Davide Comoletti</dc:creator>
<dc:creator>Joost Schymkowitz</dc:creator>
<dc:creator>Tom Theys</dc:creator>
<dc:creator>Joris de Wit</dc:creator>
<dc:creator>Pierre Vanderhaeghen</dc:creator>
<dc:date>2023-12-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>LRRC37B is a human modifier of voltage-gated sodium channels and axon excitability in cortical neurons</dc:title>
<dc:identifier>pmid:38134874</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.028</dc:identifier>
</item>
<item>
<title>EBV and MS: The evidence is growing stronger</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38134873/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231225071446&amp;v=2.18.0
      <description>Autoimmune cross-reaction of specific antibodies to Epstein-Barr virus (EBV) has been associated with development of multiple sclerosis (MS). In this issue of Cell, Vietzen et al. identify additional immunological regulatory mechanisms that protect against autoimmunity in healthy people but are reduced in MS cases. The results confirm the link between EBV and MS.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Dec 21;186(26):5675-5676. doi: 10.1016/j.cell.2023.11.023.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Autoimmune cross-reaction of specific antibodies to Epstein-Barr virus (EBV) has been associated with development of multiple sclerosis (MS). In this issue of Cell, Vietzen et al. identify additional immunological regulatory mechanisms that protect against autoimmunity in healthy people but are reduced in MS cases. The results confirm the link between EBV and MS.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38134873/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231225071446&v=2.18.0">38134873</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.023>10.1016/j.cell.2023.11.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38134873</guid>
<pubDate>Fri, 22 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Paul J Farrell</dc:creator>
<dc:date>2023-12-22</dc:date>
<dc:source>Cell</dc:source>
<dc:title>EBV and MS: The evidence is growing stronger</dc:title>
<dc:identifier>pmid:38134873</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.023</dc:identifier>
</item>
<item>
<title>Recognized Outstanding Reviewers for Circulation in 2023</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38133534/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231225071446&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 22. doi: 10.1161/CIRCULATIONAHA.123.068502. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38133534/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231225071446&v=2.18.0">38133534</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068502>10.1161/CIRCULATIONAHA.123.068502</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38133534</guid>
<pubDate>Fri, 22 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Darren K McGuire</dc:creator>
<dc:creator>James A de Lemos</dc:creator>
<dc:creator>Joseph A Hill</dc:creator>
<dc:date>2023-12-22</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Recognized Outstanding Reviewers for Circulation in 2023</dc:title>
<dc:identifier>pmid:38133534</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068502</dc:identifier>
</item>
<item>
<title>In Vivo Silencing of Regulatory Elements Using a Single AAV-CRISPRi Vector</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38131200/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231225071446&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Dec 22. doi: 10.1161/CIRCRESAHA.123.323854. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38131200/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231225071446&v=2.18.0">38131200</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323854>10.1161/CIRCRESAHA.123.323854</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38131200</guid>
<pubDate>Fri, 22 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>P Laurette</dc:creator>
<dc:creator>C Cao</dc:creator>
<dc:creator>D Ramanujam</dc:creator>
<dc:creator>M Schwaderer</dc:creator>
<dc:creator>T Lueneburg</dc:creator>
<dc:creator>S Kuss</dc:creator>
<dc:creator>L Weiss</dc:creator>
<dc:creator>R Dilshat</dc:creator>
<dc:creator>E E M Furlong</dc:creator>
<dc:creator>F Rezende</dc:creator>
<dc:creator>S Engelhardt</dc:creator>
<dc:creator>R Gilsbach</dc:creator>
<dc:date>2023-12-22</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>In Vivo Silencing of Regulatory Elements Using a Single AAV-CRISPRi Vector</dc:title>
<dc:identifier>pmid:38131200</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323854</dc:identifier>
</item>
<item>
<title>Using Genetics to Inform Interventions Related to Sodium and Potassium in Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38131187/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231225071446&amp;v=2.18.0
      <description>CONCLUSIONS: The data suggest that genetic risk in sodium and potassium pathways could be used in a precision medicine model to direct interventions more specifically in the management of hypertension. Intervention studies are warranted.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 22. doi: 10.1161/CIRCULATIONAHA.123.065394. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Hypertension is a key risk factor for major adverse cardiovascular events but remains difficult to treat in many individuals. Dietary interventions are an effective approach to lower blood pressure (BP) but are not equally effective across all individuals. BP is heritable, and genetics may be a useful tool to overcome treatment response heterogeneity. We investigated whether the genetics of BP could be used to identify individuals with hypertension who may receive a particular benefit from lowering sodium intake and boosting potassium levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this observational genetic study, we leveraged cross-sectional data from up to 296 475 genotyped individuals drawn from the UK Biobank cohort for whom BP and urinary electrolytes (sodium and potassium), biomarkers of sodium and potassium intake, were measured. Biologically directed genetic scores for BP were constructed specifically among pathways related to sodium and potassium biology (pharmagenic enrichment scores), as well as unannotated genome-wide scores (conventional polygenic scores). We then tested whether there was a gene-by-environment interaction between urinary electrolytes and these genetic scores on BP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Genetic risk and urinary electrolytes both independently correlated with BP. However, urinary sodium was associated with a larger BP increase among individuals with higher genetic risk in sodium- and potassium-related pathways than in those with comparatively lower genetic risk. For example, each SD in urinary sodium was associated with a 1.47-mm Hg increase in systolic BP for those in the top 10% of the distribution of genetic risk in sodium and potassium transport pathways versus a 0.97-mm Hg systolic BP increase in the lowest 10% (<i>P</i>=1.95×10<sup>-</sup><sup>3</sup>). This interaction with urinary sodium remained when considering estimated glomerular filtration rate and indexing sodium to urinary creatinine. There was no strong evidence of an interaction between urinary sodium and a standard genome-wide polygenic score of BP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The data suggest that genetic risk in sodium and potassium pathways could be used in a precision medicine model to direct interventions more specifically in the management of hypertension. Intervention studies are warranted.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38131187/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231225071446&v=2.18.0">38131187</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065394>10.1161/CIRCULATIONAHA.123.065394</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38131187</guid>
<pubDate>Fri, 22 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>William R Reay</dc:creator>
<dc:creator>Erin Clarke</dc:creator>
<dc:creator>Shaun Eslick</dc:creator>
<dc:creator>Carlos Riveros</dc:creator>
<dc:creator>Elizabeth G Holliday</dc:creator>
<dc:creator>Mark A McEvoy</dc:creator>
<dc:creator>Roseanne Peel</dc:creator>
<dc:creator>Stephen Hancock</dc:creator>
<dc:creator>Rodney J Scott</dc:creator>
<dc:creator>John R Attia</dc:creator>
<dc:creator>Clare E Collins</dc:creator>
<dc:creator>Murray J Cairns</dc:creator>
<dc:date>2023-12-22</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Using Genetics to Inform Interventions Related to Sodium and Potassium in Hypertension</dc:title>
<dc:identifier>pmid:38131187</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065394</dc:identifier>
</item>
<item>
<title>RAF-like protein kinases mediate a deeply conserved, rapid auxin response</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38128538/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231225071446&amp;v=2.18.0
      <description>The plant-signaling molecule auxin triggers fast and slow cellular responses across land plants and algae. The nuclear auxin pathway mediates gene expression and controls growth and development in land plants, but this pathway is absent from algal sister groups. Several components of rapid responses have been identified in Arabidopsis, but it is unknown if these are part of a conserved mechanism. We recently identified a fast, proteome-wide phosphorylation response to auxin. Here, we show that...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Dec 13:S0092-8674(23)01275-8. doi: 10.1016/j.cell.2023.11.021. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The plant-signaling molecule auxin triggers fast and slow cellular responses across land plants and algae. The nuclear auxin pathway mediates gene expression and controls growth and development in land plants, but this pathway is absent from algal sister groups. Several components of rapid responses have been identified in Arabidopsis, but it is unknown if these are part of a conserved mechanism. We recently identified a fast, proteome-wide phosphorylation response to auxin. Here, we show that this response occurs across 5 land plant and algal species and converges on a core group of shared targets. We found conserved rapid physiological responses to auxin in the same species and identified rapidly accelerated fibrosarcoma (RAF)-like protein kinases as central mediators of auxin-triggered phosphorylation across species. Genetic analysis connects this kinase to both auxin-triggered protein phosphorylation and rapid cellular response, thus identifying an ancient mechanism for fast auxin responses in the green lineage.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38128538/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231225071446&v=2.18.0">38128538</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.021>10.1016/j.cell.2023.11.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38128538</guid>
<pubDate>Thu, 21 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Andre Kuhn</dc:creator>
<dc:creator>Mark Roosjen</dc:creator>
<dc:creator>Sumanth Mutte</dc:creator>
<dc:creator>Shiv Mani Dubey</dc:creator>
<dc:creator>Vanessa Polet Carrillo Carrasco</dc:creator>
<dc:creator>Sjef Boeren</dc:creator>
<dc:creator>Aline Monzer</dc:creator>
<dc:creator>Jasper Koehorst</dc:creator>
<dc:creator>Takayuki Kohchi</dc:creator>
<dc:creator>Ryuichi Nishihama</dc:creator>
<dc:creator>Matyáš Fendrych</dc:creator>
<dc:creator>Joris Sprakel</dc:creator>
<dc:creator>Jiří Friml</dc:creator>
<dc:creator>Dolf Weijers</dc:creator>
<dc:date>2023-12-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>RAF-like protein kinases mediate a deeply conserved, rapid auxin response</dc:title>
<dc:identifier>pmid:38128538</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.021</dc:identifier>
</item>
<item>
<title>Metabolic regulation of homologous recombination repair by MRE11 lactylation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38128537/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231225071446&amp;v=2.18.0
      <description>Lactylation is a lactate-induced post-translational modification best known for its roles in epigenetic regulation. Herein, we demonstrate that MRE11, a crucial homologous recombination (HR) protein, is lactylated at K673 by the CBP acetyltransferase in response to DNA damage and dependent on ATM phosphorylation of the latter. MRE11 lactylation promotes its binding to DNA, facilitating DNA end resection and HR. Inhibition of CBP or LDH downregulated MRE11 lactylation, impaired HR, and enhanced...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Dec 18:S0092-8674(23)01276-X. doi: 10.1016/j.cell.2023.11.022. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Lactylation is a lactate-induced post-translational modification best known for its roles in epigenetic regulation. Herein, we demonstrate that MRE11, a crucial homologous recombination (HR) protein, is lactylated at K673 by the CBP acetyltransferase in response to DNA damage and dependent on ATM phosphorylation of the latter. MRE11 lactylation promotes its binding to DNA, facilitating DNA end resection and HR. Inhibition of CBP or LDH downregulated MRE11 lactylation, impaired HR, and enhanced chemosensitivity of tumor cells in patient-derived xenograft and organoid models. A cell-penetrating peptide that specifically blocks MRE11 lactylation inhibited HR and sensitized cancer cells to cisplatin and PARPi. These findings unveil lactylation as a key regulator of HR, providing fresh insights into the ways in which cellular metabolism is linked to DSB repair. They also imply that the Warburg effect can confer chemoresistance through enhancing HR and suggest a potential therapeutic strategy of targeting MRE11 lactylation to mitigate the effects.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38128537/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231225071446&v=2.18.0">38128537</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.022>10.1016/j.cell.2023.11.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38128537</guid>
<pubDate>Thu, 21 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Yuping Chen</dc:creator>
<dc:creator>Jinhuan Wu</dc:creator>
<dc:creator>Linhui Zhai</dc:creator>
<dc:creator>Tingting Zhang</dc:creator>
<dc:creator>Hui Yin</dc:creator>
<dc:creator>Huanyao Gao</dc:creator>
<dc:creator>Fei Zhao</dc:creator>
<dc:creator>Zhe Wang</dc:creator>
<dc:creator>Xiaoning Yang</dc:creator>
<dc:creator>Mingpeng Jin</dc:creator>
<dc:creator>Bingsong Huang</dc:creator>
<dc:creator>Xin Ding</dc:creator>
<dc:creator>Rui Li</dc:creator>
<dc:creator>Jie Yang</dc:creator>
<dc:creator>Yiming He</dc:creator>
<dc:creator>Qianwen Wang</dc:creator>
<dc:creator>Weibin Wang</dc:creator>
<dc:creator>Jake A Kloeber</dc:creator>
<dc:creator>Yunxuan Li</dc:creator>
<dc:creator>Bingbing Hao</dc:creator>
<dc:creator>Yuanyuan Zhang</dc:creator>
<dc:creator>Jiadong Wang</dc:creator>
<dc:creator>Minjia Tan</dc:creator>
<dc:creator>Ke Li</dc:creator>
<dc:creator>Ping Wang</dc:creator>
<dc:creator>Zhenkun Lou</dc:creator>
<dc:creator>Jian Yuan</dc:creator>
<dc:date>2023-12-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Metabolic regulation of homologous recombination repair by MRE11 lactylation</dc:title>
<dc:identifier>pmid:38128537</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.022</dc:identifier>
</item>
<item>
<title>Correction to: Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38127058/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231225071446&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 21:ehad855. doi: 10.1093/eurheartj/ehad855. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38127058/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231225071446&v=2.18.0">38127058</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad855>10.1093/eurheartj/ehad855</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38127058</guid>
<pubDate>Thu, 21 Dec 2023 06:00:00 -0500</pubDate>
<dc:date>2023-12-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry</dc:title>
<dc:identifier>pmid:38127058</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad855</dc:identifier>
</item>
<item>
<title>A conundrum of arterialized capillaries and vascular dilation in chronic limb-threatening ischaemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38126898/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231225071446&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 21:ehad826. doi: 10.1093/eurheartj/ehad826. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38126898/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231225071446&v=2.18.0">38126898</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad826>10.1093/eurheartj/ehad826</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38126898</guid>
<pubDate>Thu, 21 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Vijay C Ganta</dc:creator>
<dc:creator>W Schuyler Jones</dc:creator>
<dc:creator>Brian H Annex</dc:creator>
<dc:date>2023-12-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A conundrum of arterialized capillaries and vascular dilation in chronic limb-threatening ischaemia</dc:title>
<dc:identifier>pmid:38126898</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad826</dc:identifier>
</item>
<item>
<title>Induced Endothelial Cell CycleArrest Prevents Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38126211/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231225071446&amp;v=2.18.0
      <description>CONCLUSIONS: This study provides new insights into molecular mechanisms leading to HHT by defining how endothelial cell cycle is dysregulated in AVMs because of BMP9/10 and Alk1 signaling deficiencies, and how restoration of endothelial cell cycle control may be used to treat AVMs in patients with HHT.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 21. doi: 10.1161/CIRCULATIONAHA.122.062952. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Distinct endothelial cell cycle states (early G1 versus late G1) provide different "windows of opportunity" to enable the differential expression of genes that regulate venous versus arterial specification, respectively. Endothelial cell cycle control and arteriovenous identities are disrupted in vascular malformations including arteriovenous shunts, the hallmark of hereditary hemorrhagic telangiectasia (HHT). To date, the mechanistic link between endothelial cell cycle regulation and the development of arteriovenous malformations (AVMs) in HHT is not known.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used BMP (bone morphogenetic protein) 9/10 blocking antibodies and endothelial-specific deletion of activin A receptor like type 1 (<i>Alk1</i>) to induce HHT in Fucci (fluorescent ubiquitination-based cell cycle indicator) 2 mice to assess endothelial cell cycle states in AVMs. We also assessed the therapeutic potential of inducing endothelial cell cycle G1 arrest in HHT to prevent AVMs by repurposing the Food and Drug Administration-approved CDK (cyclin-dependent kinase) 4/6 inhibitor (CDK4/6i) palbociclib.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We found that endothelial cell cycle state and associated gene expressions are dysregulated during the pathogenesis of vascular malformations in HHT. We also showed that palbociclib treatment prevented AVM development induced by BMP9/10 inhibition and <i>Alk1</i> genetic deletion. Mechanistically, endothelial cell late G1 arrest induced by palbociclib modulates the expression of genes regulating arteriovenous identity, endothelial cell migration, metabolism, and VEGF-A (vascular endothelial growth factor A) and BMP9 signaling that collectively contribute to the prevention of vascular malformations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study provides new insights into molecular mechanisms leading to HHT by defining how endothelial cell cycle is dysregulated in AVMs because of BMP9/10 and Alk1 signaling deficiencies, and how restoration of endothelial cell cycle control may be used to treat AVMs in patients with HHT.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38126211/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231225071446&v=2.18.0">38126211</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.062952>10.1161/CIRCULATIONAHA.122.062952</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38126211</guid>
<pubDate>Thu, 21 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Gael Genet</dc:creator>
<dc:creator>Nafiisha Genet</dc:creator>
<dc:creator>Umadevi Paila</dc:creator>
<dc:creator>Shelby R Cain</dc:creator>
<dc:creator>Aleksandra Cwiek</dc:creator>
<dc:creator>Nicholas W Chavkin</dc:creator>
<dc:creator>Vlad Serbulea</dc:creator>
<dc:creator>Agnès Figueras</dc:creator>
<dc:creator>Pau Cerdà</dc:creator>
<dc:creator>Stephanie P McDonnell</dc:creator>
<dc:creator>Danya Sankaranarayanan</dc:creator>
<dc:creator>Mahalia Huba</dc:creator>
<dc:creator>Elizabeth A Nelson</dc:creator>
<dc:creator>Antoni Riera-Mestre</dc:creator>
<dc:creator>Karen K Hirschi</dc:creator>
<dc:date>2023-12-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Induced Endothelial Cell CycleArrest Prevents Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia</dc:title>
<dc:identifier>pmid:38126211</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.062952</dc:identifier>
</item>
<item>
<title>Single-Cell RNA Sequencing Reveals Metabolic Stress-Dependent Activation of Cardiac Macrophages in a Model of Dyslipidemia-Induced Diastolic Dysfunction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38126199/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231225071446&amp;v=2.18.0
      <description>CONCLUSIONS: Using single-cell RNA sequencing , in a model of diastolic dysfunction driven by hyperlipidemia, we have determined the effects of metabolic distress on cardiac inflammatory cells, in particular on macrophages, and suggest sodium glucose cotransporter-2 inhibitors as potential therapeutic agents for the targeting of a specific phenotype of HFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 21. doi: 10.1161/CIRCULATIONAHA.122.062984. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Metabolic distress is often associated with heart failure with preserved ejection fraction (HFpEF) and represents a therapeutic challenge. Metabolism-induced systemic inflammation links comorbidities with HFpEF. How metabolic changes affect myocardial inflammation in the context of HFpEF is not known.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We found that ApoE knockout mice fed a Western diet recapitulate many features of HFpEF. Single-cell RNA sequencing was used for expression analysis of CD45<sup>+</sup> cardiac cells to evaluate the involvement of inflammation in diastolic dysfunction. We focused bioinformatics analysis on macrophages, obtaining high-resolution identification of subsets of these cells in the heart, enabling us to study the outcomes of metabolic distress on the cardiac macrophage infiltrate and to identify a macrophage-to-cardiomyocyte regulatory axis. To test whether a clinically relevant sodium glucose cotransporter-2 inhibitor could ameliorate the cardiac immune infiltrate profile in our model, mice were randomized to receive the sodium glucose cotransporter-2 inhibitor dapagliflozin or vehicle for 8 weeks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: ApoE knockout mice fed a Western diet presented with reduced diastolic function, reduced exercise tolerance, and increased pulmonary congestion associated with cardiac lipid overload and reduced polyunsaturated fatty acids. The main immune cell types infiltrating the heart included 4 subpopulations of resident and monocyte-derived macrophages, determining a proinflammatory profile exclusively in ApoE knockout- Western diet mice. Lipid overload had a direct effect on inflammatory gene activation in macrophages, mediated through endoplasmic reticulum stress pathways. Investigation of the macrophage-to-cardiomyocyte regulatory axis revealed the potential effects on cardiomyocytes of multiple inflammatory cytokines secreted by macrophages, affecting pathways such as hypertrophy, fibrosis, and autophagy. Finally, we describe an anti-inflammatory effect of sodium glucose cotransporter-2 inhibitor in this model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Using single-cell RNA sequencing , in a model of diastolic dysfunction driven by hyperlipidemia, we have determined the effects of metabolic distress on cardiac inflammatory cells, in particular on macrophages, and suggest sodium glucose cotransporter-2 inhibitors as potential therapeutic agents for the targeting of a specific phenotype of HFpEF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38126199/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231225071446&v=2.18.0">38126199</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.062984>10.1161/CIRCULATIONAHA.122.062984</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38126199</guid>
<pubDate>Thu, 21 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Cristina Panico</dc:creator>
<dc:creator>Arianna Felicetta</dc:creator>
<dc:creator>Paolo Kunderfranco</dc:creator>
<dc:creator>Marco Cremonesi</dc:creator>
<dc:creator>Nicolò Salvarani</dc:creator>
<dc:creator>Pierluigi Carullo</dc:creator>
<dc:creator>Federico Colombo</dc:creator>
<dc:creator>Alessandra Idini</dc:creator>
<dc:creator>Mauro Passaretti</dc:creator>
<dc:creator>Riccardo Doro</dc:creator>
<dc:creator>Marcello Rubino</dc:creator>
<dc:creator>Alessandro Villaschi</dc:creator>
<dc:creator>Giorgio Da Rin</dc:creator>
<dc:creator>Clelia Peano</dc:creator>
<dc:creator>Marinos Kallikourdis</dc:creator>
<dc:creator>Carolina M Greco</dc:creator>
<dc:creator>Gianluigi Condorelli</dc:creator>
<dc:date>2023-12-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Single-Cell RNA Sequencing Reveals Metabolic Stress-Dependent Activation of Cardiac Macrophages in a Model of Dyslipidemia-Induced Diastolic Dysfunction</dc:title>
<dc:identifier>pmid:38126199</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.062984</dc:identifier>
</item>
<item>
<title>Ago2 Protects Against Diabetic Cardiomyopathy by Activating Mitochondrial Gene Translation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38126189/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231225071446&amp;v=2.18.0
      <description>CONCLUSIONS: Our findings reveal that the SIRT3-Ago2-CYTB axis links glucotoxicity to cardiac electron transport chain imbalance, providing new mechanistic insights and the basis to develop mitochondria targeting therapies for diabetic cardiomyopathy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 21. doi: 10.1161/CIRCULATIONAHA.123.065546. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Diabetes is associated with cardiovascular complications. microRNAs translocate into subcellular organelles to modify genes involved in diabetic cardiomyopathy. However, functional properties of subcellular Ago2 (Argonaute2), a core member of miRNA machinery, remain elusive.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We elucidated the function and mechanism of subcellular localized Ago2 on mouse models for diabetes and diabetic cardiomyopathy. Recombinant adeno-associated virus type 9 was used to deliver Ago2 to mice through the tail vein. Cardiac structure and functions were assessed by echocardiography and catheter manometer system.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Ago2 was decreased in mitochondria of diabetic cardiomyocytes. Overexpression of mitochondrial Ago2 attenuated diabetes-induced cardiac dysfunction. Ago2 recruited <i>TUFM</i>, a mitochondria translation elongation factor, to activate translation of electron transport chain subunits and decrease reactive oxygen species. Malonylation, a posttranslational modification of Ago2, reduced the importing of Ago2 into mitochondria in diabetic cardiomyopathy. Ago2 malonylation was regulated by a cytoplasmic-localized short isoform of <i>SIRT3</i> through a previously unknown demalonylase function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings reveal that the <i>SIRT3</i>-Ago2-<i>CYTB</i> axis links glucotoxicity to cardiac electron transport chain imbalance, providing new mechanistic insights and the basis to develop mitochondria targeting therapies for diabetic cardiomyopathy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38126189/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231225071446&v=2.18.0">38126189</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065546>10.1161/CIRCULATIONAHA.123.065546</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38126189</guid>
<pubDate>Thu, 21 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Jiabing Zhan</dc:creator>
<dc:creator>Kunying Jin</dc:creator>
<dc:creator>Rong Xie</dc:creator>
<dc:creator>Jiahui Fan</dc:creator>
<dc:creator>Yuyan Tang</dc:creator>
<dc:creator>Chen Chen</dc:creator>
<dc:creator>Huaping Li</dc:creator>
<dc:creator>Dao Wen Wang</dc:creator>
<dc:date>2023-12-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Ago2 Protects Against Diabetic Cardiomyopathy by Activating Mitochondrial Gene Translation</dc:title>
<dc:identifier>pmid:38126189</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065546</dc:identifier>
</item>
<item>
<title>Intravenous iron repletion in heart failure: bridging the gap between symptom relief and hard clinical outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38124672/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231225071446&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 21;44(48):5092-5094. doi: 10.1093/eurheartj/ehad746.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38124672/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231225071446&v=2.18.0">38124672</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad746>10.1093/eurheartj/ehad746</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38124672</guid>
<pubDate>Thu, 21 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Huda Abu-Own</dc:creator>
<dc:creator>Ian Webb</dc:creator>
<dc:creator>Darlington O Okonko</dc:creator>
<dc:date>2023-12-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intravenous iron repletion in heart failure: bridging the gap between symptom relief and hard clinical outcomes</dc:title>
<dc:identifier>pmid:38124672</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad746</dc:identifier>
</item>
<item>
<title>Sodium-glucose cotransporter 2 inhibitors, weight loss therapies, and ferric carboxymaltose: new light shed on innovative ways to reduce cardiovascular risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38124671/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231225071446&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 21;44(48):5009-5014. doi: 10.1093/eurheartj/ehad815.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38124671/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231225071446&v=2.18.0">38124671</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad815>10.1093/eurheartj/ehad815</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38124671</guid>
<pubDate>Thu, 21 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-12-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sodium-glucose cotransporter 2 inhibitors, weight loss therapies, and ferric carboxymaltose: new light shed on innovative ways to reduce cardiovascular risk</dc:title>
<dc:identifier>pmid:38124671</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad815</dc:identifier>
</item>
<item>
<title>Dual Antiplatelet Therapy De-Escalation in Stabilized Myocardial Infarction With High Ischemic Risk: Post Hoc Analysis of the TALOS-AMI Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38117483/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231225071446&amp;v=2.18.0
      <description>CONCLUSIONS AND RELEVANCE: In stabilized patients with AMI, the ischemic and bleeding outcomes of an unguided de-escalation strategy with clopidogrel compared with a ticagrelor-based DAPT strategy were consistent without significant interaction, regardless of the presence of high ischemic risk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Dec 20:e234587. doi: 10.1001/jamacardio.2023.4587. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: In patients with acute myocardial infarction (AMI) who have high ischemic risk, data on the efficacy and safety of the de-escalation strategy of switching from ticagrelor to clopidogrel are lacking.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the outcomes of the de-escalation strategy compared with dual antiplatelet therapy (DAPT) with ticagrelor in stabilized patients with AMI and high ischemic risk following percutaneous coronary intervention (PCI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of the Ticagrelor vs Clopidogrel in Stabilized Patients With Acute Myocardial Infarction (TALOS-AMI) trial, an open-label, assessor-blinded, multicenter, randomized clinical trial. Patients with AMI who had no event during 1 month of ticagrelor-based DAPT after PCI were included. High ischemic risk was defined as having a history of diabetes or chronic kidney disease, multivessel PCI, at least 3 lesions treated, total stent length greater than 60 mm, at least 3 stents implanted, left main PCI, or bifurcation PCI with at least 2 stents. Data were collected from February 14, 2014, to January 21, 2021, and analyzed from December 1, 2021, to June 30, 2022.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Patients were randomly assigned to either de-escalation from ticagrelor to clopidogrel or ticagrelor-based DAPT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Ischemic outcomes (composite of cardiovascular death, myocardial infarction, ischemic stroke, ischemia-driven revascularization, or stent thrombosis) and bleeding outcomes (Bleeding Academic Research Consortium type 2, 3, or 5 bleeding) were evaluated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 2697 patients with AMI (mean [SD] age, 60.0 [11.4] years; 454 [16.8%] female), 1371 (50.8%; 684 assigned to de-escalation and 687 assigned to ticagrelor-based DAPT) had high ischemic risk features and a significantly higher risk of ischemic outcomes than those without high ischemic risk (1326 patients [49.2%], including 665 assigned to de-escalation and 661 assigned to ticagrelor-based DAPT) (hazard ratio [HR], 1.74; 95% CI, 1.15-2.63; P = .01). De-escalation to clopidogrel, compared with ticagrelor-based DAPT, showed no significant difference in ischemic risk across the high ischemic risk group (HR, 0.88; 95% CI, 0.54-1.45; P = .62) and the non-high ischemic risk group (HR, 0.65; 95% CI, 0.33-1.28; P = .21), without heterogeneity (P for interaction = .47). The bleeding risk of the de-escalation group was consistent in both the high ischemic risk group (HR, 0.64; 95% CI, 0.37-1.11; P = .11) and the non-high ischemic risk group (HR, 0.42; 95% CI, 0.24-0.75; P = .003), without heterogeneity (P for interaction = .32).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In stabilized patients with AMI, the ischemic and bleeding outcomes of an unguided de-escalation strategy with clopidogrel compared with a ticagrelor-based DAPT strategy were consistent without significant interaction, regardless of the presence of high ischemic risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38117483/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231225071446&v=2.18.0">38117483</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC10733848/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231225071446&v=2.18.0">PMC10733848</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4587>10.1001/jamacardio.2023.4587</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38117483</guid>
<pubDate>Wed, 20 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Myunhee Lee</dc:creator>
<dc:creator>Sungwook Byun</dc:creator>
<dc:creator>Sungmin Lim</dc:creator>
<dc:creator>Eun Ho Choo</dc:creator>
<dc:creator>Kwan Yong Lee</dc:creator>
<dc:creator>Donggyu Moon</dc:creator>
<dc:creator>Ik Jun Choi</dc:creator>
<dc:creator>Byung-Hee Hwang</dc:creator>
<dc:creator>Chan Joon Kim</dc:creator>
<dc:creator>Mahn-Won Park</dc:creator>
<dc:creator>Yun Seok Choi</dc:creator>
<dc:creator>Hee-Yeol Kim</dc:creator>
<dc:creator>Ki-Dong Yoo</dc:creator>
<dc:creator>Doo-Soo Jeon</dc:creator>
<dc:creator>Hyeon Woo Yim</dc:creator>
<dc:creator>Kiyuk Chang</dc:creator>
<dc:creator>TALOS-AMI Investigators</dc:creator>
<dc:date>2023-12-20</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Dual Antiplatelet Therapy De-Escalation in Stabilized Myocardial Infarction With High Ischemic Risk: Post Hoc Analysis of the TALOS-AMI Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38117483</dc:identifier>
<dc:identifier>pmc:PMC10733848</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4587</dc:identifier>
</item>





























</channel>
</rss>